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This work is licensed under a Creative Commons Attribution 4.0 LicenseAlzheimer’s 
disease (AD) is the most common form of dementia in the elderly and its prevalence 
is set to increase rapidly in coming decades. However, there are as yet no available 
drugs that can halt or even stabilize disease progression. One of the main pathological 
features of AD is the presence in the brain of senile plaques mainly composed of 
aggregated β amyloid (Aβ), a derivative of the longer amyloid precursor protein 
(APP). The amyloid hypothesis proposes that the accumulation of Aβ within neural 
tissue is the initial event that triggers the disease. Here we review research efforts that 
have attempted to inhibit the generation of the Aβ peptide through modulation of 
the activity of the proteolytic secretases that act on APP and discuss whether this is a 
viable therapeutic strategy for treating AD.
Alzheimer’s disease (AD) is the most common form of dementia in the elderly but as 
yet there are no drugs that can halt the progression of this disease. In a theory called 
the ‘amyloid hypothesis’, researchers have proposed that the accumulation of a small 
protein fragment called beta amyloid or Aβ within brain tissue is the event which 
triggers Alzheimer’s disease. Aβ is a derivative of the longer amyloid precursor protein 
(APP). Here we review research efforts that have attempted to inhibit the generation 
of Aβ through modulation of proteins called secretases which cut APP into Aβ. 
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Alzheimer’s disease (AD) is the most common 
form of dementia in the elderly and accounts 
for between 50 and 75% of all cases. By 2030 
it is estimated that more than 65 million peo-
ple will be living with dementia, with pro-
jections almost doubling every 20 years [1,2]. 
AD is a disorder characterized by the loss of 
neurons, mainly in the hippocampus and 
cerebral cortex [3]. The symptoms of the dis-
ease include erosion of memory and of other 
cognitive functions such as language and 
reasoning, as well as neuropsychiatric mani-
festations such as delusions and apathy [2,4]. 
In addition to its role in neurodegeneration, 
AD is the fourth most common cause of 
death in industrialized nations, preceded by 
cardiovascular disease, cancer and stroke [4]. 
The increasing burden of AD has resulted in 
intensive efforts by the scientific community 
to develop therapeutic agents to prevent the 
progression of the disease. However, as yet, 
there are no available drugs that can halt or 
even stabilize disease progression. Here we 
review research efforts that have attempted 
to inhibit the generation of the beta amyloid 
peptide through modulation of the activity 
of the proteolytic secretases that act on the 
amyloid precursor protein (APP) and discuss 
whether this is a viable therapeutic strategy 
for treating AD.
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Alzheimer’s disease was first described by Alois 
Alzheimer in 1907 [5]. Since then, its key pathologi-
cal features have been shown to be senile plaques and 
neurofibrillary tangles, as well as ventricular dilation 
and atrophy of neural tissue [6]. The plaques’ main 
proteinaceous component is aggregated beta amyloid 
(Aβ), a derivative of the longer APP. The plaques are 
found primarily within the neocortex of the affected 
brain. Neurofibrillary tangles are accumulations of tau 
protein which are mainly located in or surrounding the 
hippocampus.
AD can be either familial, or sporadic. Familial 
cases of AD (FAD) have been traced back to muta-
tions that alter the secretion of Aβ within the brain [7]. 
Similarly, other predisposing factors involved in spo-
radic AD have also been shown to affect Aβ. These 
results, together with the presence of Aβ within the 
senile plaques, have led to the formulation of the amy-
loid hypothesis as the leading model for AD [8]. The 
roles of α, β and γ-secretase play an essential part in 
this model.
The amyloid hypothesis
The amyloid hypothesis was first proposed over 20 
years ago [9]. It describes the accumulation of Aβ 
within neural tissue as the initial event that triggers 
the disease [8]. The accumulation is the result of an 
imbalance between Aβ production and clearance, 
which leads to the aggregation of Aβ and the forma-
tion of plaques which, in turn, cause the formation of 
neurofibrillary tangles [9]. The hypothesis was formed 
following two keystone observations: first, the identifi-
cation of Aβ as the primary proteinaceous component 
of senile plaques [10] and, second, the identification 
of several mutations in familial AD that lead to the 
accumulation of Aβ [11–13].
Aβ is a derivative of the larger APP [14]. Aβ was first 
discovered in 1983 as part of senile plaques in patients 
with AD [15] and again in the brains of patients with 
Down’s syndrome. This established the first link 
between AD and Down’s syndrome and also led to 
the conclusion that the gene containing Aβ would 
have to be located on chromosome 21 [16]. APP was 
identified in 1987 as a ~700 residue transmembrane 
protein. Since no other physiological function of this 
protein was known, except as the precursor to Aβ, 
it was simply designated APP. Its original function 
is still unclear. APP is expressed widely in normal 
human tissues including in the heart, lung, liver and 
skin [17]. The APP gene is located on chromosome 21, 
resulting in four-to-fivefold overexpression of APP 
in patients with trisomy 21 [18]. This explains the 
Aβ overproduction and early development of AD in 
individuals with Down’s syndrome [14]. These results 
strongly implicated the deregulation of APP expres-
sion as a factor in AD development. APP, and all its 
related proteins, are single-pass transmembrane pro-
teins with large extracellular domains. There are eight 
differently spliced isoforms of APP. The one most 
commonly expressed in the central nervous system 
(CNS) is the 695-residue isoform [19]. APP in itself 
is not neurotoxic, and does not produce Aβ until it 
undergoes proteolytic cleavage. It is produced in con-
siderable quantities in neurons, where it is sorted via 
the Golgi and then shipped toward the axons [20]. APP 
can undergo cleavage in three different locations: at 
the N-terminal of the Aβ domain via β-secretase; at 
the C-terminal of the Aβ domain via γ-secretase; and 
within the Aβ domain via α-secretase. Proteolytic 
cleavage by α-secretase does not produce complete Aβ 
and, therefore, does not lead to the development of 
AD (Figure 1). Cleavage by β- and γ-secretase how-
ever yields several isoforms of the Aβ peptide that can 
aggregate into senile plaques [21]. 
Aβ itself is a 4-kDa peptide [22] that is primarily pro-
duced in neurons [23]. The Aβ domain in APP is located 
toward the C-terminal of the precursor protein [24], and 
is released extracellularly following cleavage by β and 
γ-secretase. The two most prevalent isoforms of Aβ are 
40 and 42 residues in length. The two forms differ at the 
C terminal, where length is determined by the cleavage 
site of γ-secretase [25]. While Aβ40 is more common, 
the 42 residue isoform is the primary component of 
senile plaques as is it highly prone to aggregation [26,27]. 
Once released, Aβ will accumulate to form first oligo-
mers, then fibrils and finally plaques of protein [28]. 
The amyloid plaques appear to then cause hyperphos-
phorylation of microtubule-associated tau protein. 
This causes the protein to accumulate and form neu-
rofibrillary tangles, which cause synaptic dysfunction 
and contribute considerably to AD symptoms [29,30]. 
Thus, deposition of Aβ in neural tissue is a sufficient 
trigger event for the progression of Alzheimer’s disease, 
according to the amyloid hypothesis.
In support of the hypothesis, a number of FAD 
associated missense mutations in APP have been char-
acterized which induce changes in APP processing, 
resulting in increased Aβ production (Figure 2). The 
most notable of these are the KM670/671NL (Swed-
ish) mutation and mutations at valine 717 including 
V717I (London) and V717F (Indiana) which frame 
the Aβ sequence [31–33]. The Swedish double muta-
tion at the β-secretase cleavage site results in a six-
to-eightfold increase in secreted Aβ peptide levels 
compared with wild-type APP. Other FAD associ-
ated APP mutations include: E693Q (Dutch); E693K 
(Italian), E693G (Arctic), D694N (Iowa) and A692G 
(Flemish) [31,33–38].
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While the Flemish mutation induces a two-fold 
increase in Aβ
1–40
 and Aβ
1–42
 production due to reduced 
α-secretase activity (Figure 2), the Dutch and Iowa 
mutations do not alter levels of Aβ
1–40
 or Aβ
1–42
 relative 
to wild-type APP but are associated with accelerated 
fibril formation and increased pathogenicity from the 
resultant Aβ peptides [37,39–41]
While much is still left unanswered, for example, 
the physical connection between the formation of 
senile plaques and that of neurofibrillary tangles has 
not yet been explained, the amyloid hypothesis is sup-
ported by much experimental data and remains the 
most commonly accepted model for AD. Despite some 
drawbacks with the hypothesis, alternative hypotheses 
explaining pathogenesis of the disease have not been 
as robust. Therapies targeting Aβ amyloidogenesis 
have the theoretical potential to slow or even prevent 
further neurodegeneration, and the development of 
anti-Aβ therapeutics is regarded as a logical approach 
to the treatment of AD [9,42]. Here we look at the 
characterization of the secretases involved in APP 
processing and examine their ongoing therapeutic 
potential.
α-secretase
The processing pathway of APP was long presumed 
to include a putative α-secretase – an enzyme that 
could cleave APP within the Aβ domain. This enzyme 
was known to be a metalloprotease that localized 
to the cell membrane and the Golgi complex. The 
α-secretase cleaves APP at residue L688, located in 
the middle of the Aβ domain (Figure 1). Cleavage 
through α-secretase can therefore not produce com-
plete Aβ [43]. Instead it releases the soluble extracellular 
domain of APP (sAPPα) in a process called ‘ectodo-
main shedding’ [44]. This ectodomain is presumed to 
have neuroprotective properties [45]. The remaining 
membrane-bound C-terminal fragment of APP (C83) 
is then cleaved by γ-secretase to release a nontoxic p3 
peptide [23]. Cleavage by α-secretase occurs in both a 
regulated and constitutive manner. Regulated cleavage 
occurs in the Golgi Complex under control of protein 
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Figure 1. Amyloid precursor protein processing. The sequential proteolytic degradation of amyloid precursor proteins results in the 
generation of Aβ peptides, ultimately leading to the progression of Alzheimer’s disease. Black arrows represent nonamyloidogenic 
processing of amyloid precursor protein and red arrows represent the amyloidogenic pathway.
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kinase C (PKC) [44,46], while constitutive cleavage 
occurs very rapidly at the cell membrane [44]. The 
first candidate enzyme for α-secretase was proposed 
in 1998 when ADAM17, also known as tumor necro-
sis factor-converting enzyme (TACE), was shown to 
have α-secretase activity, primarily within the Golgi 
Complex, that was regulated by PKC[47]. The exis-
tence of other α-secretases was presumed. In 1999 two 
more enzymes were shown to have α-secretase activ-
ity: ADAM9 and ADAM10 [44,48–49]. Like ADAM 17, 
both of them are part of the a-disintegrin and metal-
loprotease family (ADAM). All three of these enzymes 
have been confirmed as active α-secretases [49,50]. Ini-
tial knockdown of the candidate α-secretases seemed 
to demonstrate that release of sAPPα was never fully 
abolished, and initially it was concluded that the can-
didate α secretases showed significant functional over-
lap [49,51,52]. However, a more recent study showed that 
ADAM10, but not ADAM9 or 17, is essential for the 
constitutive α-secretase cleavage of APP and it has 
been concluded that ADAM10 is probably the most 
physiologically relevant α-secretase in neurons [51,53].
Therapeutic potential of α-secretase
As α-secretase processing of APP involves cleavage 
within the Aβ peptide sequence, precluding Aβ for-
mation, activation of APP a-secretase cleavage is con-
sidered an obvious potential treatment for AD [51]. 
Such activation would be presumed to both lower 
levels of Aβ and increase levels of the neuroprotective 
sAPPα [54].
Evidence for the rationale of such an approach 
comes from a study in which moderate overexpres-
sion of ADAM10 in an APP mouse model was shown 
to reduce levels of Aβ and prevented its deposition in 
plaques, as well as improving cognitive defects [54,55]. 
In addition, ADAM10 activity has been shown to be 
decreased in the platelet and spinal fluid of AD patients 
in accordance with disease progression [56,57]. Further-
more, a decrease in α-secretase has been demonstrated 
in sporadic AD brain samples [58].
Despite recent clarification of the role of ADAM10 
in neurons, there is ongoing uncertainty over the 
potential effects of extensive activation of these pro-
teases [59]. ADAM10 alone has been shown to cleave 
over 30 different substrates[54,60,61] and is thought to 
be widely expressed in non-neural tissues [62,63]. How-
ever, interestingly, studies have indicated that a num-
ber of the current drugs in use for treatment of AD can 
increase the activity of α-secretases via the activation 
of associated signaling cascades and it has so far been 
considered that this may represent the best therapeutic 
approach [52,64,65]. Selegiline, a selective monoamine 
oxidase inhibitor used to slow the progression of AD, 
has been shown to increase α-secretase activity via a 
protein trafficking related mechanism [66,67]. Atorvas-
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Figure 2. Amyloid precursor protein mutations that alter amyloid precursor protein processing. Examples of mutations in the amyloid 
precursor protein that alter its interactions with secretases, leading to altered production of Aβ peptides. The majority of mutations 
in the APP gene are pathogenic but the recently discovered Icelandic mutation confers a protective effect.
www.future-science.com 10.4155/FSO.15.9 future science group
The role & therapeutic targeting of α-, β- & γ-secretase in Alzheimer’s disease    Review
tatin, used to treat AD after it was shown that chronic 
statin use may be protective, also appears to induce 
activation of α-secretase [68,69].
A number of drugs intended as indirect α-secretase 
activators have progressed to the clinical trials stage 
for AD. The most prominent has been etazolate (EHT 
0202), an GABA receptor modulator, which has 
reached Phase II human clinical trials after previously 
having been shown to stimulate sAPPα production 
and protect against Aβ induced toxicity in rat cortical 
neurons [70,71]. PRX-03140, a 5-HT4 agonist known 
to stimulate α-secretase, showed positive results in 
a Phase II trial in 2008 with improvement in cogni-
tion in AD patients, but no further studies have been 
announced [72]. NCT00951834 or epigallocatechin-
gallate (EGCG), a polyphenolic compound from green 
tea, has also been shown to stimulate α-secretase via the 
PKC pathway and reduce cerebral amyloid deposition 
in AD mice [73–75]. Phase II/III trials investigating the 
benefit of this drug in AD are currently underway [73]. 
Finally bryostatin, a powerful PKC modulator known 
to increase the secretion of the α-secretase product 
(sAPPα), is currently undergoing Phase II trials for use 
in AD, with no results published to date [76].
β-secretase
Akin to the situation for α-secretase, the involve-
ment of β-secretase in APP processing has long been 
presumed. Several characteristics of this enzyme were 
known before the discovery of the enzyme itself. 
β-secretase was known to be widely expressed [77], but 
expression was most prominent in the pancreas and 
brain, especially in neurons [78,79]. Within cells it was 
expected to be localized to endosomes, lysosomes and 
the Golgi Complex [80,81] and to function optimally at 
an acidic pH [82].
In 1999 an enzyme which matched all these charac-
teristics and showed proteolytic activity at the correct 
site on APP was discovered. The β-site APP Cleaving 
Enzyme (BACE1) was proposed as a likely candidate for 
β-secretase by four separate studies [24,83–85]. BACE1 
is a transmembrane aspartic protease. It is about 500 
residues in length with two active sites located on 
the lumenal side of the membrane. This allows the 
enzyme ready access to its substrate within the lumen 
of the Golgi, where it competes with α-secretase for 
APP, or within endosomes and lysosomes [24,26]. The 
putative β-secretase enzyme was known to be highly 
sequence specific [86,87], a characteristic that matches 
with BACE1, which cleaves APP at the N-terminal of 
the Aβ domain, either at residue Asp672 or Glu682 
(Figure 1). This matches the most commonly found iso-
forms of Aβ [24]. As with α-secretase, cleavage of APP 
by BACE1 releases the soluble extracellular domain 
of APP (sAPPβ), however, the complete Aβ domain 
remains attached to the membrane-bound C-terminal 
fragment (C99) [23]. C99 is then cleaved by γ-secretase 
to release one of several Aβ isoforms, most commonly 
Aβ
1–40
 and Aβ
1–42
 [27].
BACE1 activity has been shown to be elevated in 
cases of sporadic AD [88,89]. However, β-secretase is not 
exclusively active in individuals with AD. Instead it 
appears to be producing Aβ during normal cell metab-
olism [77]. Therefore, the cause of AD is not simply the 
activation of β-secretase and its production of Aβ, but 
rather a change in the amount of APP processed by 
β-secretase. This could be due to mutations that reduce 
cleavage by α-secretase, favoring β-secretase instead, as 
can be seen in cases of familial AD [86,90] (Figure 2). It 
could also be caused by a shift toward differentially 
spliced APP, again favoring β-secretase processing, or 
simply due to an increase in APP expression [18].
Therapeutic potential of β-secretase
The findings detailed above make BACE1 a primary 
target for drug research, as inhibition of the enzyme 
would effectively block Aβ production. Treatment of 
other diseases such as HIV using protease inhibitors 
had previously been successful and use of the same 
approach for BACE1 seemed promising [91]. BACE1 -/- 
homozygous knockout mice had originally displayed 
no adverse effects due to the absence of BACE1, which 
seemed to indicate that full inhibition may be toler-
able [92,93]. BACE1 -/- mice fail to produce Aβ, do not 
develop amyloid plaques, and the knockout is able to 
rescue several phenotypes of AD-prone mice [94].
The past decade has therefore seen intense research 
efforts towards BACE1 inhibition. The crystal struc-
ture of BACE1 was initially used to develop the first 
generation of BACE1 peptidomimetic inhibitors [95]. 
These compounds seemed to show potent inhibitory 
activity and high selectivity [52]; however, as the active 
site of BACE1 is large, the required large molecular 
sizes also caused low membrane permeability across the 
blood–brain barrier (BBB) [95–97]. The development of 
smaller nonpeptidic inhibitors, with low enough molec-
ular weights to allow for easier penetration of the BBB 
while still retaining a high affinity for the active site 
of BACE1 proved to be a long and difficult challenge. 
Achieving sufficient selectivity was another challeng-
ing issue, not least over BACE2, a BACE1 homolog 
with which it shares 64% identity [98–100]. Eventually 
such problems were overcome with the development of 
a small compound named CTS-21166 by CoMentis 
which possessed sufficient brain penetrability as well 
as high oral availability and selectivity. Phase I trials 
were conducted in 2008 and reductions in plasma Aβ 
levels of greater than 60% were announced, however 
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no further studies have been planned for undisclosed 
reasons [101]. Eli Lily’s LY2886721 initially showed 
reduction in plasma Aβ levels but had to be abandoned 
in July 2013 following Phase II trial due to liver toxic-
ity [102]. Eisai’s E2609 Phase I demonstrated a reduc-
tion in plasma Aβ levels as well as a dose-dependent 
reduction in Aβ CSF levels but Phase II trials have not 
yet been announced [103]. Development of TransTech 
Pharma’s HPP854 and of Roche’s RG7129 was termi-
nated following Phase I trials for undisclosed reasons. 
Two BACE inhibitors have so far progressed to Phase 
II/III trial. Merck’s MK-8931 began Phase II/III trial 
in November 2012 following successful reductions in 
the CSF levels of Aβ
1–40
 and Aβ
1–42
 during Phase II [104]. 
In November 2013, it was announced that the drug 
had passed initial safety evaluation and would progress 
to a second Phase III study. In September 2014, Astra 
Zeneca and Eli Lily announced the commencement of 
a large Phase II/III trial of Astra Zeneca’s AZD3293 
following claims of an encouraging safety profile and 
reduction in CSF levels of Aβ
1–40
 and Aβ
1–42
 during 
Phase I trial [105].
While these results have provided an encouraging 
proof-of-concept reduction in Aβ in humans follow-
ing BACE1 inhibition, concerns over potential side 
effects from this approach have grown with time and 
increased understanding of the physiological role of 
this enzyme [106]. More recent animal studies seem to 
implicate BACE1 in the formation and maintenance of 
muscle spindle formation [107] and show cognitive and 
memory problems in homozygous knockout mice that 
were not apparent in previous studies [108,109]. BACE1 
knockout mice also display significantly higher mor-
tality rates in their first weeks of life [110]. The pro-
gression of research into this enzyme has shown that 
BACE1 has a number of important alternative sub-
strates, including proteins involved in myelination 
and sodium homeostasis [111,112]. This suggests a risk 
of morbidity with long-term BACE1 inhibition. The 
question may be whether the benefits of BACE1 inhi-
bition outweigh the side effects in an elderly popu-
lation. This has led to interesting speculation as to 
whether a partial rather than extensive inhibition of 
BACE1 activity may be enough to reduce Aβ lev-
els [52,98]. Studies on mouse models seemed to indicate 
this might be a feasible approach. One study used het-
erozygous BACE1 gene knockout (BACE1+/−) mice to 
demonstrate that a 50% BACE1 reduction is sufficient 
to rescue deficits in brain function in an AD transgenic 
mouse model, 5XFAD[113]. A further study of BACE1 
heterozygote mice overexpressing mutant human APP 
(PDAPP;BACE1+/−) showed a considerable reduction 
in brain Aβ levels and plaque load as compared with 
PDAPP;BACE1+/+ mice [114]. Heterozygous BACE1 
knockout (BACE1+/−) mice appear to be healthy and 
do not demonstrate the phenotype shown the in more 
recent studies of BACE1-/- mice [109–110,112]. These data 
seemed to indicate that limited inhibition of BACE1 
may represent a more viable approach. However, a 
more recent study showed that the phenotypic res-
cue and decreased Aβ burden associated with BACE1 
haplo-insufficiency in the 5XFAD model may decline 
with age [115]. Therefore, further studies into the effects 
of partial suppression of BACE1 will be required to 
determine whether this is a feasible strategy.
The long wait for a successful, clinically beneficial 
inhibitor of BACE1 has caused many to question the 
validity of this protein as a target, and even to question 
the validity of the amyloid hypothesis itself [116,117]. 
Encouragingly, it was recently shown that a single resi-
due mutation within the APP gene which reduces the 
ability of β-secretase to cleave APP confers a strongly 
protective effect against both AD and general cognitive 
decline in a human population [118], which many have 
taken as further support of the amyloid hypothesis and 
of BACE1 as a therapeutic target in AD.
γ-secretase
The putative γ-secretase is an enzyme that cleaves the 
C-terminal fragment of APP following cleavage by 
either α or β-secretase to release the APP cytoplas-
mic domain [7]. Before its identity was confirmed, 
the protein was known to be fairly nonspecific in the 
sequences it would bind and cleave, producing diver-
gent C-terminals in Aβ isoforms [7]. It was also known 
to be influenced by presenilin 1 and 2 (PS-1 and 
PS-2), which appeared to determine where at the Aβ 
C-terminal γ-secretase would cleave the protein.
The putative γ-secretase enzyme constituted a riddle 
in earlier years, as it appeared to be cleaving the APP 
C-terminal fragment within the hydrophobic environ-
ment of the plasma membrane [7]. It was finally shown 
to be a protein complex, and a founding member of a 
new class of intramembrane-cleaving proteases [119]. In 
this protein complex, presenilin represents the active 
site after being cleaved into an N- and a C-terminal 
fragment that associates into a heterodimer [120] with 
aspartic protease activity [121]. The proteins nicastrin 
(NCSTN) [122,123], anterior pharynx-defective 1 (APH-
1) [124] and presenilin enhancer 2 (PEN-2) [125] were 
also found to associate with the presenilins to form the 
γ-secretase complex (Figure 1). The components of the 
γ-secretase complex are widely expressed in a variety 
of tissues out with the brain including liver, heart and 
lung [126,127]. All of the presenilin-associated proteins 
are embedded in the membrane [123–125]. The substrate 
passes in between the two presenilin fragments which 
appear to form a hydrophilic pocket in the membrane 
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that allows for the proteolytic cleavage to occur [128,129]. 
Presenilin mutations appear to be the main cause of 
familial AD with more than 150 causative mutations 
having been mapped to the genes encoding the prese-
nilin proteins, PSEN1 and 2 [130,131]. This is suggestive 
of a key role for the γ-secretase complex, at least in the 
familial form of AD. Most such mutations appear to 
increase production of Aβ
1–42
 over Aβ
1–40
 by promoting 
cleavage at residue 639 of APP over residue 637 [132].
Therapeutic potential of γ-secretase
As with β-secretase, inhibition of γ-secretase represents 
an obvious logical strategy for inhibiting the generation 
of Aβ. Notwithstanding its status as a protein complex, 
the development of potent γ-secretase inhibitors able 
to cross the blood–brain barrier proved fairly sim-
ple [133,134,135]. However, γ-secretase had been shown to 
cleave a wide range of substrates, carrying out a much 
broader function than originally anticipated [136,137]. 
By far the most significant of these substrates is Notch, 
a cell surface signalling receptor that is essential for 
many aspects of cell development and differentia-
tion [138,139,140,141], and which may also play a role in 
tumour suppression [142]. For these reasons, potential 
problems with toxicity in γ-secretase inhibition had 
long been predicted [52].
Indeed thus far clinical trials of γ-secretase inhibitors 
have demonstrated significant adverse effects as well as 
lack of positive effect on cognition [143]. γ-secretase has 
been the most commonly studied anti-amyloid target 
in clinical trials but as yet no improvement in cognitive 
function or slowing of cognitive decline has been con-
firmed [144]. In a recent high profile failure, Eli Lily’s 
semagacestat (LY450139) was discontinued after two 
Phase III trials demonstrated not only failure to slow 
disease progression but also significant cognitive wors-
ening [145]. An increased incidence of skin cancer was 
also reported, most likely due to concomitant Notch 
inhibition. Development of Bristol-Myers-Squibb’s 
avagacestat (BMS708163) was halted in November 
2012 after Phase II trials, again due to lack of positive 
effect on cognition, worsening cognition and increased 
risk of skin cancer [143,146].
As with β-secretase inhibition, such high profile, 
disappointing results for inhibition of γ-secretase 
have prompted serious questions about the feasibility 
of therapeutically targeting this complex as an AD 
strategy and have also prompted considerable debate 
over the long and expensive pursuit of the amyloid 
hypothesis as the central dogma in AD research [147].
The future of γ-secretase inhibition as an AD 
treatment strategy may depend on two newer strate-
gies: first, the successful development of APP selec-
tive ‘Notch-sparing’ γ-secretase inhibitor compounds, 
capable of lowering Aβ levels without inhibiting the 
processing of Notch [148]; second, the development of 
γ-secretase modulators, which aim to cause a shift from 
Aβ
1–42
 species toward the shorter and less pathogenic 
forms of Aβ, while also sparing Notch [149].
Results so far have not been encouraging. Avagace-
stat was initially thought to act as a Notch-sparing 
γ-secretase inhibitor but later studies showed this to be 
false [150]. A clinical trial for the Notch-sparing inhibitor 
ELND006 (Elan Corporation) was halted in 2010 due 
to liver toxicity [151]. A second Notch-sparing inhibitor, 
Begacestat (GSI-953) demonstrated lowered Aβ levels 
in the CSF during Phase I trial but development was 
discontinued in late 2010 [152]. The γ-secretase modula-
tor Tarenflurbil showed positive results on cognition in 
Phase II but was terminated after Phase III trials due 
to poor results [153–155]. Chiesi’s γ-secretase modulator 
CHF-5074 reached Phase II trials but was halted for 
undisclosed reasons [156]. A further γ-secretase modula-
tor, NIC5–15, is in Phase II trials with results yet to 
be announced [157]. Despite the poor results with ear-
lier drugs hope still remains around this modulatory 
approach.
Conclusion
From the information reviewed here it remains far 
from certain whether targeting the secretases involved 
in APP processing will yield the ground breaking 
therapeutic that is urgently required to treat AD. The 
number of high-profile failures in recent years has 
severely impacted the confidence of large pharmaceu-
tical companies in the continuation of research and 
development programs in the neuroscience area and a 
number of companies have scaled back their risk in this 
field. Nonetheless, the potential rewards for discover-
ing a drug to treat AD prevent a full retreat by key 
players.
Pharmacological attempts to target Aβ clear-
ance through mechanisms to induce active or pas-
sive immunity have produced similar negative results 
leading to more recent high profile clinical failures, 
namely Bapineuzumab, developed by Johnson & 
Johnson and Pfizer [158] and Solanezumab, developed 
by Eli Lilly [159], both of which failed their primary end 
points in Phase III.
The amyloid hypothesis has now been the mainstay 
of therapeutic research in Alzheimer’s disease for over 
two decades. The series of high profile clinical failures 
has inevitably called into question the viability of the 
hypothesis itself. A number of issues have plagued the 
amyloid hypothesis since its inception. First, the level 
of Aβ burden does not often correlate with clinical 
manifestation of the disease. In several studies amyloid 
plaques were apparent in control samples from humans 
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despite no evidence of cognitive decline [160–163]. How-
ever, other investigations have found a much stronger 
correlation between levels of soluble Aβ oligomers and 
severity of cognitive decline [164,165].
Second, the difficulty in isolating the specific neuro-
toxic species of Aβ and characterizing its effects makes 
research problematic. Early studies demonstrated that 
aggregation of Aβ is essential for the cytotoxic effects 
of Aβ [166] but it was also noted that different prepara-
tions result in different potencies of the Aβ peptide [167]. 
Furthermore, soluble intermediate species of synthetic 
Aβ are made up of several distinct conformations 
which appear to have differential neurotoxic effects on 
cultured neurons. These include: oligomers composed 
of 15–20 monomers; small diffusible Aβ oligomers 
known as ADDLs (Aβ-derived diffusible ligands); and 
protofibrils (strings of oligomers) [168–171].
Further criticism of the evidence underpinning the 
amyloid hypothesis revolves around the current trans-
genic mouse models of AD, which do not fully reca-
pitulate the disease. Despite increased Aβ deposition in 
these models, there appears to be a lack of coincidental 
neuronal loss. This is thought to be due mainly to spe-
cies differences in neuronal susceptibility to Aβ accu-
mulation, a lack of the human tau protein in mice, as 
well as the lack of a human-like inflammatory response 
which also plays a pivotal role in the progression of the 
disease [9].
Critics of the primacy of the amyloid hypothesis 
in AD research have argued that a simplistic focus on 
this one approach may have diverted attention from 
other important associations in AD. Some argue that 
while APP processing is of great importance, the spo-
radic form of AD might in future be more properly 
understood as a complex failure with age of multiple 
interacting physiological systems, some of which may 
share an underlying pathology [172]. For example, a 
strong association between the incidence of Type 2 
diabetes (T2D) and AD [173] has led to a desire for a 
better understanding of the shared pathology of dis-
eases which involve the aggregation of misfolded pro-
teins and a speculation that such diseases may share 
complex downstream interactions. Similarly, there 
is increasing recognition of the role of endoplasmic 
reticulum (ER) stress and dysregulation of ER func-
tion in AD pathology and it has been observed that 
the restoration of ER stress markers by the bile acid 
TUDCA (tauroursodeoxycholic acid) seems to pre-
vent AB dependent neurotoxicity in experimental 
models [174,175]. That the brain physiology underlying 
AD pathology is governed by multiple factors would 
hardly be surprising in an organ as functionally and 
structurally complex as the brain, and it is to be hoped 
that a greater understanding of associated physiologi-
cal systems and disease states in AD will lead to fur-
ther therapeutic targeting approaches out with the 
direct components of APP processing and AB deposi-
tion. Yet an increased understanding of the potentially 
multifactorial interactions of physiological systems in 
AD has also lent some further support to the secre-
tase targeting approach and may even yet suggest more 
gentle modulatory approaches to their inhibition. For 
example, focus on the associations between T2D and 
AD led to a recognition that the impaired insulin sig-
naling associated with AD may lead to an increase in 
the activity of GSK-3 [176]. GSK-3 inhibitors are recog-
nized as a promising treatment strategy in AD due to 
GSK-3’s promotion of tau hyperphosphorylation and 
potential role in the formation of NFTs [177]. How-
ever, it has also been recognized that GSK-3 seems to 
regulate AB production, possibly due to its ability to 
interact with the presenilins and regulate the activity 
of the γ-secretase complex [177,178]. In addition, GSK-3 
inhibition has been shown to reduce β-secretase cleav-
age of APP and Aβ production by decreasing BACE1 
expression [178]. GSK-3 inhibition may represent a fur-
ther modulatory strategy in the inhibition of secretase 
activity. Similarly, the strong neuroprotective effect 
conferred by TUDCA may be due to its inhibition of 
connective tissue growth factor (CTGF), a complex 
which enhances γ-secretase activity, raising the sug-
gestion that the targeting of CTGF might represent a 
further approach in γ-secretase modulation [179].
In support of the importance of the amyloid 
hypothesis, the most significant high-profile discovery 
of recent years has been the aforementioned identi-
fication of a protective mutation in APP (A673T) in 
an Icelandic population which significantly reduces 
BACE1 cleavage of APP as compared with wild-type 
APP (Figure 2) [180]. This discovery was seen as provid-
ing proof of principle that reducing the amyloidogenic 
processing of APP has a protective effect and appeared 
to strongly support the idea that targeting BACE1 in 
the sporadic form of the disease is a justified approach. 
Much of the prior genetic evidence had related to the 
rarer early onset familial form of AD.
Further support for the amyloid hypothesis was 
demonstrated with the recent development of a novel 
three-dimensional human neural culture model of 
AD. This human neural stem-cell derived culture 
system showed that familial APP mutations induced 
robust Aβ deposition and led to high levels of deter-
gent-resistant phospho-tau in the soma and neurites. 
In this model, inhibition of Aβ generation using β- 
or γ-secretase inhibitors not only reduced Aβ deposi-
tion but also attenuated the generation of aggregated 
phospho-tau [181]. Although this is only a single cell 
system, it further highlights the potential efficacy 
www.future-science.com 10.4155/FSO.15.9 future science group
The role & therapeutic targeting of α-, β- & γ-secretase in Alzheimer’s disease    Review
of the β- and γ-secretase inhibitors and adds weight 
to the hope that highly selective therapeutics with 
minimal off-target effects still may have potential to 
treat AD.
One major issue that has been highlighted by the 
failures of so many AD clinical trials is the design 
of the trials themselves. It is now generally accepted 
that a large number of the clinical trials of AD treat-
ments may have failed due to the patients’ being too 
far advanced in the disease process to see any clinical 
effect from a potential therapeutic. Amyloid deposi-
tion in AD is now thought to begin many years before 
the appearance of cognitive symptoms and ultimate 
diagnosis of dementia [182]. Much drug development 
in AD is now beginning to focus on the targeting of 
patients at the very early stages of the disease, before 
obvious dementia, particularly in groups with familial 
AD. As such, the FDA have produced guidance for the 
design of clinical trials involving patients who do not 
present with overt dementia. In a New England Jour-
nal of Medicine (NEJM) editorial, authors of the FDA’s 
report suggested that assessment of cognitive function 
might productively be combined with assessment of 
certain biomarkers such as levels of Aβ plaque load in 
the brain, measured by positron-emission tomography 
or levels of Aβ and tau in the cerebrospinal fluid [183]. 
It will be interesting to see whether some of the pre-
viously failed APP secretase targeting drugs will have 
clinical efficacy when executed in newly designed 
clinical trials.
One consideration is that if relatively healthy 
people are to be utilized as subjects in the drug 
discovery process, the prospect of ongoing prob-
lems with potential side effects could become even 
more serious. It is not yet clear what level of β or 
γ-secretase reduction may be required to achieve suf-
ficient reduction in brain Aβ and whether this will 
bring with it an acceptable level of side effects. The 
suspension of the BACE1 inhibitor LY2886721 due 
to liver toxicity was initially assumed to be due to 
off target effects yet worryingly it was recently sug-
gested that this effect may have come about due to 
BACE1’s cleavage of beta-galactoside alpha 2,6-sial-
yltransferase (ST6Gal1) within the liver [184]. While 
BACE1 is expressed most highly in the brain and 
pancreas it is expressed at some level in all tissues 
and important functions may extend beyond the 
brain [185]. Therefore, it may be that strategies that 
allow for tissue-specific regulation of BACE1 should 
be considered in future efforts to target this protein. 
The components of the γ-secretase complex are also 
widely expressed [186]. One suggested strategy for tis-
sue-specific regulation of the APP secretases relates to 
the dysfunction of the ubiquitin proteasome system 
seen in many neurodegenerative diseases including 
AD [187]. BACE1 and the PS, PEN-2 and APH-1 com-
ponents of the γ-secretase complex are all thought to 
be turned over via the ubiquitin proteasome degrada-
tion system (UPS) [188,189], raising the attractive pos-
sibility of regulating levels of these proteins via their 
associations with the highly tissue and substrate spe-
cific deubiquitinating enzymes that underlie protein 
turnover within the UPS.
Future perspective
There is no question of the vast unmet clinical need 
for AD, particularly due to the socioeconomic burden 
associated with caring for people afflicted with the 
condition. Proponents of the amyloid hypothesis argue 
that the clinical trial data to date has not yet adequately 
tested the hypothesis; it is not yet clear whether trial 
failure was due to ineffective late intervention, to 
drug side effects masking effects on cognition, or to 
inadequate engagement of the target secretases by the 
drugs, rather than to a failure of the amyloid hypoth-
esis itself. The outcomes of current earlier intervention 
trials may be key to the continued focus on the amy-
loid hypothesis as the central tenet of AD research. 
Further high profile clinical failures could potentially 
result in the withdrawal of major pharmaceutical com-
panies from the funding of anti-Aβ clinical trials. Any 
major success would doubtless be regarded as justifi-
cation of the effort and resources used in the pursuit 
of anti-Aβ therapies over the last decade. Any success 
in a secretase-targeting early intervention trial which 
came at a cost of significant side effects in relatively 
healthy individuals might well lead to a renewed focus 
on more indirect modulatory approaches to secretase 
inhibition, and to a further increase in efforts to deter-
mine high quality biomarkers for the development of 
the disease. Despite the recent failures in clinical trials 
significant hope yet lies around the secretase targeting 
approach.
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